Susquehanna International Group, LLP Chinook Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	SELL	$18.66 - $38.58 $2.04 Million - $4.21 Million	-109,200 Reduced 79.77%	27,700 $1.06 Million
Q1 2023 May 16, 2023	BUY	$21.53 - $26.8 $2.42 Million - $3.02 Million	112,600 Added 463.37%	136,900 $3.17 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $4.16 Million - $6.11 Million	-223,300 Reduced 90.19%	24,300 $636,000
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $2 Million - $2.66 Million	-114,000 Reduced 31.53%	247,600 $4.87 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $4.2 Million - $6.27 Million	333,600 Added 1191.43%	361,600 $6.32 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $180,300 - $250,350	15,000 Added 115.38%	28,000 $458,000
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $6,900 - $8,916	-600 Reduced 4.41%	13,000 $166,000
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $161,840 - $284,376	13,600 New	13,600 $216,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.